Global phase 3 trial of zoliflodacin

The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical
Read More